Billiontoone, Inc. (NASDAQ:BLLN) Receives Average Rating of “Moderate Buy” from Brokerages

Billiontoone, Inc. (NASDAQ:BLLN) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $126.00.

A number of research firms have recently weighed in on BLLN. Guggenheim started coverage on shares of Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective for the company. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. boosted their price target on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, BTIG Research reduced their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th.

Insiders Place Their Bets

In other Billiontoone news, CTO David Tsao sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00. Following the sale, the chief technology officer directly owned 1,000 shares of the company’s stock, valued at approximately $102,270. This trade represents a 95.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $125.00, for a total value of $1,000,000.00. Following the completion of the sale, the insider directly owned 204,000 shares in the company, valued at approximately $25,500,000. The trade was a 3.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 153,049 shares of company stock valued at $16,768,021.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Adams Street Partners LLC acquired a new stake in shares of Billiontoone in the fourth quarter worth approximately $140,063,000. Baillie Gifford & Co. purchased a new stake in Billiontoone in the fourth quarter valued at approximately $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone during the fourth quarter worth approximately $39,717,000. JPMorgan Chase & Co. purchased a new position in Billiontoone during the fourth quarter worth approximately $32,078,000. Finally, Wasatch Advisors LP purchased a new position in Billiontoone during the first quarter worth approximately $29,179,000.

Billiontoone Trading Down 2.8%

Shares of BLLN stock opened at $123.25 on Tuesday. The company has a market capitalization of $5.67 billion and a price-to-earnings ratio of 224.09. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $101.46 and a 200 day moving average price of $89.09. Billiontoone has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. Billiontoone’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.39) earnings per share. Research analysts forecast that Billiontoone will post 0.93 earnings per share for the current fiscal year.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.